Clinical Study on Raman Spectra of Blood, Saliva and Urine in Patients With Cancer Treated by Modern Therapy

Breast Cancer Clinical Trial

Official title:

Clinical Study on Raman Spectra of Blood, Saliva and Urine in Patients With Cancer Treated by Modern Therapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04215861
• Other study ID #: PJ-KS-KY-2019-135
• Status: Recruiting
• Start date: October 1, 2019
• Est. completion date: October 2021

Study information

• Verified date: December 2019
• Source: The First Affiliated Hospital of Dalian Medical University
• Contact: Xiaonan Cui, MD,PhD
• Phone: +8618098876725
• Email: cxn23[@]sina.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Blood, saliva and urine samples of tumor patients on the day of admission and discharge were collected for Raman spectral analysis, which provided exploration for the prediction of efficacy, follow-up and prognosis according to the variation characteristics of Raman spectral.

Description:

Blood, saliva and urine samples of tumor patients on the day of admission and discharge were collected for Raman spectral analysis, which provided exploration for the prediction of efficacy, follow-up and prognosis according to the variation characteristics of Raman spectral

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: October 2021
• Est. primary completion date: October 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• 18-80 years old;

• The patient whose tumor (tissue or cell) was first diagnosed by pathology;

• Plan to receive routine clinical treatment: chemotherapy, radiotherapy, surgery, intervention, targeted therapy, traditional Chinese medicine treatment and biological immunotherapy;

• Have relevant indications for treatment and have no contraindications;

Exclusion Criteria:

• Severe or uncontrollable systemic diseases (such as unstable or uncompensated respiratory, heart, liver or kidney diseases, etc.);

• Other circumstances considered inappropriate by the researcher to participate in the study;

Related Conditions & MeSH terms

• Breast Cancer
• Liver Cancer
• Lung Cancer
• Stomach Cancer
• Stomach Neoplasms

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Dalian Medical University	Dalian	Liaoning

Sponsors (1)

Lead Sponsor	Collaborator
The First Affiliated Hospital of Dalian Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Raman spectra	Blood, saliva and urine samples of tumor patients on the day of admission and discharge were collected to analyze the signal changes of Raman spectrum	the 1st day before operation
Primary	Raman spectra	Blood, saliva and urine samples of tumor patients on the day of admission and discharge were collected to analyze the signal changes of Raman spectrum	the 1st day after operation
Secondary	progression-free survival		through study completion, an average of 1 year
Secondary	overall survival		through study completion, an average of 1 year
Secondary	objective response rate		through study completion, an average of 1 year